70 results
Page 2 of 4
PRE 14A
cb27n9vwg4
1 Sep 21
Preliminary proxy
4:46pm
8-K
EX-1.1
g1adhqeqtl1xv
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
x8cans5b7n6ime0a
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
aw9mi42ki2dq190
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
ciraa2er f22ofjsa
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
1zps2pedy4eud
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
uva5wzm96a2rl9
5 Oct 20
Prospectus supplement with pricing info
4:16pm